# Omniome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/omniome

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.omniome.com
- Total disclosed funding: $100M
- Latest round: Series C (Nov 27, 2019)
- Investors on record: 9

## About

Founded in 2013 and based in California, US, Omniome, Inc. is a biotechnology company that develops DNA sequencing technologies for cancer diagnostics. The company was founded by Kandaswamy Vijayan. In 2019, Omniome, Inc. raised USD 60 million in Series C funding led by new investor Madrone Capital Partners, with participation from existing investors. In July 2021, Pacific Biosciences of California, Inc. signed a definitive agreement to acquire Omniome, Inc.

The company offers a DNA sequencing technology for cancer diagnostics that delivers accurate sequencing. It also operates Sequencing By Binding (SBB) technology, a solution that enhances the precision of nucleotide and DNA matching.

The company's revenue is generated by the sales of its DNA sequencing solution to its target market for industries engaged in clinical sequencing.

The acquisition of Pacific Biosciences of California, Inc. by Omniome, Inc. will help in the expansion of its technology to a wider market range.

## Funding rounds

- Series C, Nov 27, 2019, $60M — ARCH Venture Partners, Domain Associates, Altitude Life Science Ventures, Madrone Capital Partners, Decheng Capital, Biomatics Capital Partners, Nan Fung Life Sciences
- Series B, Jun 28, 2018, $40M — ARCH Venture Partners, Domain Associates, Altitude Life Science Ventures, Hillhouse Investment, Decheng Capital, Biomatics Capital Partners, Lam Research Corporation, Nan Fung Life Sciences
- Seed, Jun 30, 2016 — Altitude Life Science Ventures, Biomatics Capital Partners

## Investors

- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Seed, Series B, Series C
- Biomatics Capital Partners (https://capitalatlas.ai/funds/biomatics-capital-partners) — Seed, Series B, Series C
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B, Series C
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series C
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B, Series C
- Lam Research Corporation — Series B
- Nan Fung Life Sciences — Series B, Series C
- Madrone Capital Partners — Series C